NX-5948 received Fast Track designation from the FDA
NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foundation for advancement in CLL
Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK-4 for rheumatoid arthritis
Formed strategic collaboration with Seagen (now Pfizer) to advance a portfolio of degrader-antibody conjugates based on our industry-leading DELigase platform
Achieved $100 million in non-dilutive capital from partners in 2023, including $60 million upfront from Seagen and $40 million in success-based milestones and licensing fees from Gilead and Sanofi
Maintained strong financial position with cash and investments of $295.3 million
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.